ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
-0,01%
Bitcoin
60.858,36
0,10%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) News

ALLO

Allogene Therapeutics (ALLO)

Allogene Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ALLO
DatumZeitQuelleÜberschriftSymbolFirma
06/05/202414h30GlobeNewswire Inc.Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
26/04/202414h30GlobeNewswire Inc.Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaNASDAQ:ALLOAllogene Therapeutics Inc
09/04/202414h30GlobeNewswire Inc.Allogene Therapeutics Announces Q2 Investor Conference ParticipationNASDAQ:ALLOAllogene Therapeutics Inc
14/03/202421h05GlobeNewswire Inc.Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
12/03/202413h30GlobeNewswire Inc.Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseNASDAQ:ALLOAllogene Therapeutics Inc
05/03/202414h30GlobeNewswire Inc.Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
28/02/202414h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
16/02/202414h30GlobeNewswire Inc.Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaNASDAQ:ALLOAllogene Therapeutics Inc
31/01/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
24/01/202423h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
22/01/202422h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
16/01/202422h05GlobeNewswire Inc.Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
05/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202422h15GlobeNewswire Inc.Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
04/01/202422h05GlobeNewswire Inc.Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
03/01/202422h05GlobeNewswire Inc.Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
20/12/202322h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
19/12/202321h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
18/12/202322h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
09/12/202318h00GlobeNewswire Inc.Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
01/12/202314h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in December Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
03/11/202317h00GlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202321h02GlobeNewswire Inc.Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
02/11/202314h00GlobeNewswire Inc.Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
30/10/202313h30GlobeNewswire Inc.Allogene Therapeutics Announces Participation in November Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALLO

Kürzlich von Ihnen besucht

NASDAQ
GOOGL
Alphabet
DBI
SDXP
SDAX
NASDAQ
AAPL
Apple
DBI
MDAX
MDAX
AMEX
SPY
SPDR S&P 500
FX
EURUSD
Euro vs US Dollar
TG
MBG
MercedesBenz
TG
BAS
BASF
TG
LHA
Deutsche Lufthansa
NASDAQ
NVDA
NVIDIA
COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
NASDAQ
MSFT
Microsoft
AMEX
XLE
Energy Select Sector SPDR
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten